Supporting your NASH/NAFLD drug development programs using a chimeric mouse model with a humanized liver.
At PhoenixBio, we understand the complexities of building robust NASH/NAFLD drug development programs. With the disease’s many complex factors, it is challenging to discern underlying mechanisms and identify clinically significant biomarkers. Currently available animal models tend to lack key disease characteristics such as hepatocyte ballooning/fibrosis, and have lengthy timescales in presenting fibrosis after high-fat diets.
Our humanized liver chimeric mouse model enables you to overcome research and translation issues affecting the development of therapeutic agents within the growing NASH/NAFLD study fields. With two fully characterized models of diet-induced NASH, the PXB-mouse® presents the ideal model for the straightforward evaluation of drug efficacy and toxicity in a human-relevant environment. Importantly, the PXB-mouse® has a human-like lipoprotein profile, further strengthening its relevance as a NAFLD/NASH model.
Our dedicated project management teams will work with you to provide timely delivery of validated data, ensuring you receive the support you need to design and execute your NASH/NALFD drug development programs with PXB-mice.
Our unique chimeric PXB-mouse® with a humanized liver is a next-generation research tool that exhibits human NASH-like disease related histopathological changes including hepatocyte ballooning, mallory-denk bodies, perisinusoidal fibrogenesis, and inflammation — offering you a comprehensive validation method for pre-clinical NASH/NAFLD research studies.
The PXB-mouse® allows you to better understand the human liver condition with NASH/NAFLD, identify clinically significant biomarkers to better predict the disease and bring therapeutic agents to market.
Induce human-like NASH symptoms in PXB from 12 weeks with the choline-deficient, high-fat diet (CBAHFD), and 20-30 weeks with the Gubra-Amylin Nash (GAN) diet, closely resembling the slow onset of fibrosis caused by the ‘Western diet’ in humans.
PXB-mice have a chimeric humanized liver environment containing up to 97% human hepatocytes. Their human-like lipoprotein profile makes them an ideal model to test human outcomes of NASH/NAFLD drug development programs.
Recapitulate the NASH phenotype observed in humans in our chimeric mouse model with a humanized liver. Our PXB-mice fed on a high-fat diet show human-like hepatocyte ballooning and other characteristics not typically observed in rodents.
Recapitulate the NASH phenotype observed in humans in our chimeric mouse model with a humanized liver. Our PXB-mice are fed a high-fat diet show human-like hepatocyte ballooning and other characteristics not typically observed in rodents.
Our PXB-mice have helped to drive many NASH/NAFLD drug discovery projects and enabled organizations to achieve accurate human liver environment data.